Back to Screener

Healthcare

Connect Biopharma Holdings Limited(CNTB)

Live Price

Offline

$2.10

-0.94% today

1Y Change

+105.97%

Window

Jun 26, 2025 โ†’ Jun 18, 2026

Market Cap
$140.00M
Revenue Growth
-99.8%
EPS Growth
-257.1%
Dividend Yield
0.0%

Coverage: 246 bars ยท Jun 26, 2025 โ†’ Jun 18, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Connect Biopharma Holdings Limited (CNTB) is a Healthcare stock with a market cap of $140.00M and listed on NASDAQ. The stock last traded around $2.10 and up 106.0% across the available one-year price window (Jun 26, 2025 โ†’ Jun 18, 2026). Baseline metrics include revenue growth of -99.8%, EPS growth of -257.1%, a dividend yield of 0.0%. What stands out right now is revenue -99.8%, EPS -257.1%, free cash flow -112.0% with operating margin -60312.5% and ROIC -67.7%. Valuation already assumes a fairly strong business story at price/sales 2908.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CNTB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Edge

CNTB vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

CNTB

โ€”

Normalized return

SPY

--

S&P 500

Excess Return

--

Relative to SPY

CNTB Max Drawdown

-46.07%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for CNTB and SPY.

Calendar-year return history is still loading or unavailable.

EPS Consensus

-0.28

Range -0.28 -> -0.28

No analyst count

vs prior: -3.5%

Revenue Outlook

$0.0B

Range $0.0B -> $0.0B

No analyst count

Price Target

--

-- -> --

No analyst count

Recommendations

--

No recommendation feed

No date

Consensus Spread

EPS spread0.0%
Revenue spread--

Lower spread suggests tighter agreement across covering analysts.

Next Earnings

No date

EPS --

Revenue --

No analyst count

EPS Revisions

No revision signal

No recent EPS revision rows

0 revision rows

Trend

EPS trend

Consensus average across visible periods

-0.28
Latest visible period
Q3 2026Q4 2027
6 visible pointstrend: -3.5%

Trend

Revenue trend

Average analyst revenue estimate

$0.0B
Latest visible period
Q3 2026Q4 2027
6 visible points

Timeline

Analyst forecast ladder

Sorted by period end date. Includes both cached rows and live fallbacks from the configured analyst feed.

Q4 2027
Ends Dec 31, 2027
quarter
Revenue
$0.0B
$0.0B to $0.0B
EPS
-0.28
-0.28 to -0.28
No analyst count
EPS: No analyst count
May 5, 11:00 PM UTC
stable/analyst-estimates
Q3 2027
Ends Sep 30, 2027
quarter
Revenue
$0.0B
$0.0B to $0.0B
EPS
-0.27
-0.27 to -0.27
No analyst count
EPS: No analyst count
May 5, 11:00 PM UTC
stable/analyst-estimates
Q2 2027
Ends Jun 30, 2027
quarter
Revenue
$0.0B
$0.0B to $0.0B
EPS
-0.27
-0.27 to -0.27
No analyst count
EPS: No analyst count
May 5, 11:00 PM UTC
stable/analyst-estimates
Q1 2027
Ends Mar 31, 2027
quarter
Revenue
$0.0B
$0.0B to $0.0B
EPS
-0.27
-0.27 to -0.27
No analyst count
EPS: No analyst count
May 5, 11:00 PM UTC
stable/analyst-estimates
Q4 2026
Ends Dec 31, 2026
quarter
Revenue
$0.0B
$0.0B to $0.0B
EPS
-0.27
-0.27 to -0.27
No analyst count
EPS: No analyst count
May 5, 11:00 PM UTC
stable/analyst-estimates
Q3 2026
Ends Sep 30, 2026
quarter
Revenue
$0.0B
$0.0B to $0.0B
EPS
-0.24
-0.24 to -0.24
No analyst count
EPS: No analyst count
May 5, 11:00 PM UTC
stable/analyst-estimates

Next Step

Put consensus data in context

Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.